FRAXA Fellowship supports postdoctoral researchers worldwide in translational and preclinical Fragile X research to advance practical, disease-modifying treatments and ultimately a cure.
Funder: FRAXA Research Foundation
Due Dates: February 1, 2027 (Annual application deadline)
Funding Amounts: $60,000 per year for up to two years ($120,000 total), for direct costs
Summary: Supports postdoctoral Fragile X research, prioritizing translational and preclinical projects with potential to improve treatments.
Key Information: One application per lab group; a letter of intent and advance discussion with FRAXA are required.
The FRAXA Fellowship supports Fragile X research worldwide through FRAXA Research Foundation. Its purpose is to advance specific treatments and ultimately a cure, bringing practical treatments into medical practice as quickly as possible. Priority goes to translational or preclinical projects with clear practical applications and results that can be shared promptly with other researchers.
FRAXA emphasizes disease-modifying therapeutics grounded in an understanding of Fragile X disease mechanisms. Its priorities shift as treatment-development bottlenecks change: basic research into Fragile X mechanisms currently receives lower priority, while translational progress is emphasized. The foundation has developed standardized methods for preclinical validation and identifies clinical trials as the next bottleneck in treatment development.